Hypoparathyroidism
Conditions
Keywords
Hypoparathyroidism, Epidemiology, Medication Therapy Management
Brief summary
Very few data has been published on the epidemiology of hypoparathyroidism worldwide: none exists specifically for France. Hypoparathyroidism could led to complications. Here, the investigators plan to collect data about both epidemiology, medication and complication of hypoparathyroidism in France.
Detailed description
Very few data has been published on the epidemiology of hypoparathyroidism worldwide. None exists specifically in France. Hypoparathyroidism could led to complications: e.g. symptomatic hypocalcemia, calcifications (brain, eye and other soft tissues), nephrolithiasis/nephrocalcinosis, renal insufficiency. Here,the investigators plan to collect data about both epidemiology, medication and complication of hypoparathyroidism in France.
Interventions
OTHERNo intervention
No intervention
Sponsors
Oscar - Filière Santé Maladies Rares
European Georges Pompidou Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* patient fro whom chronic hypoparathyroidism is diagnosed * patient living in France
Exclusion criteria
* patient who does not want his data to be collected in this registry * pseudo-hypoparathyroidism * acute hypoparathyroidism
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the epidemiology of patients with hypoparathyroidism in France | Through study completion, about 2 years | Data collected by questionnaire about etiology of hypoparathyroidism, filled by physicians from clinic folders |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the biology at inclusion will describe the evolution of the included population from diagnosis to now (inclusion) | At inclusion (under treatment): through study completion, about 2 years | Number of patients with at least one anomaly at biology (calcemia in mM, calciuria in mmol/j, parathormone in pg/ml, creatininemia in µM, phosphatemia in mM, vitamin D in nmol/l & magnesemia in mM) at inclusion |
| Assessment of the management at inclusion will describe treatment and complications at inclusion | At inclusion (under treatment): through study completion, about 2 years | Number of patients with clinical outcomes (complications such as cataract, nephrolithiasis, nephrocalcinosis, and others) and their management at inclusion |
| Assessment of the biology (calcemia, calciuria, parathormone, creatininemia, phosphatemia & magnesemia) at diagnosis and drug therapy at inclusion will describe population | Through study completion, about 2 years | Number of patients with at least one anomaly at biology (calcemia in mM, calciuria in mmol/j, parathormone in pg/ml, creatininemia in µM, phosphatemia in mM, vitamin D in nmol/l & magnesemia in mM) at diagnosis |
Other
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the physician's management will help describing the habits of french physician who manage hypoparathyroidism in terms of follow-up | At inclusion | Data on habits of included physicians about their management of patients with hypoparathyroidism: frequency of complications' follow-up (nephrocalcinosis, cataract, nephrolithiasis and other calcifications) in terms of radiology (CT-scan, echotomography, radiography) and biology (calcium in mM, phosphate in mM, parathormone in pg/ml, magnesium in mM, vitamin D in nmol/l and creatininemia in µM). |
Countries
France
Contacts
Primary ContactJean-Philippe Bertocchio, MD, PhD
Backup ContactPascal Houillier, MD, PhD
Outcome results
None listed